AN2 Therapeutics, Inc. (ANTX)
| Market Cap | 195.41M +525.5% |
| Revenue (ttm) | n/a |
| Net Income | -34.88M |
| EPS | -0.90 |
| Shares Out | 37.94M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 283,908 |
| Open | 4.40 |
| Previous Close | 4.23 |
| Day's Range | 4.23 - 5.31 |
| 52-Week Range | 1.00 - 7.19 |
| Beta | -0.94 |
| Analysts | Strong Buy |
| Price Target | 9.00 (+74.76%) |
| Earnings Date | Nov 9, 2026 |
About ANTX
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company’s initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for ANTX stock is "Strong Buy." The 12-month stock price target is $9.0, which is an increase of 74.76% from the latest price.
News
AN2 Therapeutics Transcript: Jefferies Global Healthcare Conference
Three Phase II programs in PV, M. abscessus and Chagas are expected to generate proof-of-concept data in 2027, led by PV safety and efficacy updates. Earlier research includes oral ENPP1 programs in hypophosphatasia and oncology.
AN2 Therapeutics Transcript: Stifel 2026 Healthcare Conference 2026
The PV study will test dose response and hematocrit control, with initial readouts planned from Q1 2027. Three phase II programs are expected to report in 2027, while $80 million in cash was projected to fund execution into 2029.
AN2 Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
PV and Chagas Phase II programs are advancing toward data in 2027, while M. abscessus targets a major oral-treatment gap. A pan-mutant PI3K program remains in research, with development work extending into 2027.
AN2 Therapeutics reports Q3 EPS (17c), consensus (20c)
“The third quarter was marked by continued execution across our clinical pipeline and meaningful progress in expanding the opportunities enabled by our boron chemistry platform,” said Eric Easom, Co-F...
AN2 Therapeutics sees cash runway into 2029
The Company had cash, cash equivalents and investments of $80.2 million as of September 30, 2026. The Company projects that existing cash, cash equivalents, and investments will sustain operations int...
AN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific Highlights
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics der...
AN2 Therapeutics Quarterly report: Q3 2026
AN2 Therapeutics has published its Q3 2026 quarterly earnings report on November 9, 2026.
AN2 Therapeutics Earnings release: Q3 2026
AN2 Therapeutics released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
AN2 Therapeutics to Present at Jefferies Global Healthcare Conference in London
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry pla...
AN2 Therapeutics announces advancement of AN2-504661
AN2 Therapeutics (ANTX) announced the advancement of AN2-504661 as a development candidate for the treatment of HPP. AN2-504661 was selected following extensive lead optimization and preclinical evalu...
AN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical-stage biopharmaceutical company discovering and developing novel small molecule therapeutics derived from its bor...
AN2 Therapeutics receives FDA IND clearance for Phase 2 oral epetraborole study
AN2 Therapeutics (ANTX) announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug application for epetraborole in polycythemia vera. The Company has now r...
AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics der...
AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry pla...
AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics der...
AN2 Therapeutics to Participate at Upcoming Investor Conferences
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical stage biopharmaceutical company discovering and developing novel small molecule therapeutics derived from its bor...
AN2 announces extension of funding for tuberculosis research collaboration
AN2 Therapeutics (ANTX) announced that the Gates Foundation has awarded an extension of funding to support AN2 Therapeutics’ research activities under its ongoing tuberculosis research collaboration w...
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage pharmaceutical company focused on the discovery and development of small molecule therapeutics derived from...
AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry pla...
AN2 Therapeutics presents clinical data supporting development of Epetraborole
The company states: “AN2 Therapeutics (ANTX) announced that four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole, a novel boron-containing oral candidat...
AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics der...
AN2 Therapeutics appoints Trenor as Chief Medical Officer
AN2 Therapeutics (ANTX) announced the appointment of Cameron Trenor, M.D., as Chief Medical Officer. Most recently, Dr. Trenor served as Chief Medical Officer of Cellarity
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry pla...
AN2 Therapeutics reports Q2 EPS (18c), two estimates (24c)
“AN2 will have three Phase 2 programs underway by the end of this year, all of which have the potential to address major unmet needs. Our near-term focus is advancing…
AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics der...